[{"orgOrder":0,"company":"Link Cell Therapies","sponsor":"Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series A Financing","leadProduct":"LNK001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Link Cell Therapies","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Link Cell Therapies \/ Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital","highestDevelopmentStatusID":"5","companyTruncated":"Link Cell Therapies \/ Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital"},{"orgOrder":0,"company":"Link Cell Therapies","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2026","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Link Cell Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Link Cell Therapies \/ Link Cell Therapies","highestDevelopmentStatusID":"4","companyTruncated":"Link Cell Therapies \/ Link Cell Therapies"}]

Find Clinical Drug Pipeline Developments & Deals by Link Cell Therapies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : The collaboration aims to advance cell & gene therapy for solid tumors through an undisclosed lead product.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          January 09, 2026

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Nona Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : The Series A financing for LNK001, a cell & gene therapy targeting renal cell carcinoma, will advance research in this Renal Cell Carcinoma.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          December 15, 2025

                          Lead Product(s) : LNK001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Johnson & Johnson Innovative Medicine|Samsara BioCapital|Sheatree Capital|Wing Venture Capital

                          Deal Size : $60.0 million

                          Deal Type : Series A Financing

                          blank